Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of Tumor Vascular Normalization Scoring in the Response to Neoadjuvant Therapy in HER-2 Positive Breast Cancer: an Observational Study

NCT06868758 is registered in ClinicalTrials.gov with Chongqing General Hospital as lead sponsor.

NCT NCT06868758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06868758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of Tumor Vascular Normalization Scoring in the Response to Neoadjuvant Therapy in HER-2 Positive Breast Cancer: an Observational Study
Lead sponsor
Chongqing General Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
January 1, 2025
Completion date
June 30, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive breast carcinoma, neoadjuvant therapy